The Institute of Cancer Research

Cancer Research UK-funded scientists are using innovative techniques to understand how resistance to a targeted cancer drug is unfolding.

Prostate cancer screening is back in the news, as results from a targeted screening programme are released. But when it comes to yearly checks, are we there yet?

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer, according to findings presented at the ESMO conference.